Diffúz nagy B-sejtes limfóma (DLBCL): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 42
• CD20 22
• BCL-2 13
• MYC 10
• PD-1 12
• BTK 10
• TP53 7
• PD-L1 3
• CD22 7
• STAT3 0
• CD30 5
• CD47 0
• PI3K 0
• EZH2 1
• LAG-3 0
• ALK 0
• CTNNB1 0
• JAK 0
• STING 0
• BCMA 2
• EGFR 0
• METTL3 0
• mTOR 0
• AKT 0
• CD38 0
• IL-6 0
• JNK 0
• MMP-9 0
• PKM2 0
• PRMT5 0
• TIGIT 1
• TIM-3 0
• ABL1 0
• ARID1A 1
• ATM 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD40 0
• CDKN2A 0
• CTLA-4 0
• CXCR4 0
• FGFR 0
• FTO 0
• GPX4 0
• HDAC 0
• IL-1 0
• IL-15 0
• MYCN 0
• NLRP3 0
• NOTCH1 1
• PARP 0
• PINK1 0
• PPAR 0
• RAS 0
• SHP2 0
• SIRT1 0
• TERT 0
• TFEB 0

1+ intézményből 1, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R01

  Patient-Derived Models to Identify Effective Therapies in Aggressive Large B-Cell Lymphomas

  Massachusetts General Hospital· Boston, Egyesült Államok· 600 075 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Enhancing CAR-T cell therapy for DLBCL

  Washington University· Saint Louis, Egyesült Államok· 548 528 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Viral and Cellular microRNA Dependencies in HIV-associated Lymphomas

  Northwestern University· Chicago, Egyesült Államok· 644 961 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NCI · R37

  The role of MGA in the pathogenesis of Richter Transformation

  Weill Medical Coll of Cornell Univ· New York, Egyesült Államok· 425 741 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NCI · R01

  INHIBITION OF EZH2 TO ENHANCE ADOPTIVE T-CELL THERAPIES FOR CANCER

  University of Pennsylvania· Philadelphia, Egyesült Államok· 704 044 USD awarded in fiscal year 2026· until 2031. júl.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Olaszország· EU contribution 150 000 EUR· until 2028. márc.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxemburg· EU contribution 216 240 EUR· until 2028. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Development and characterization of a novel CAR T-cell therapy for NHL (CARLY)

  Fundacio Institut de Recerca Contra la Leucemia Josep Carreras· Badalona, Spanyolország· EU contribution 226 441 EUR· until 2027. jún.

• European Commission (Horizon Europe) · HORIZON-ERC

  Drivers and Brakes of CAR T Cell Efficacy Determined by the Tumor Immune Microenvironment (CAR-TIME)

  Eberhard Karls Universitaet Tuebingen· Tuebingen, Németország· EU contribution 1 499 875 EUR· until 2028. dec.

  The disease is named only in the funder's project summary, not in the title.

9 of 114 running projects, newest first. Listed amounts together: 67,4 M USD + 2,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT05626322· Pfizer· Frissítve: 2025. szept. 5.

  “The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT05626322· Pfizer· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 49
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 4
• Flow Cytometry 7
• Immunohistochemistry 36
• Liquid Biopsy 1
• Circulating Tumor DNA 12
• Xenograft Model Antitumor Assays 31
• Positron-Emission Tomography 15
• Magnetic Resonance Imaging 29
• Machine Learning 11
• Deep Learning 9
• Cohort Studies 15
• Genome-Wide Association Study 4

• Circulating Tumor DNA and Immune Response Markers for Improved Treatment Outcome Prediction in Diffuse Large B-Cell Lymphoma: A Scoping Review.

  Hematol Oncol, 2026. szept.

• Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.

  Blood Adv, 2026. júl.

• MRI Features Associated with Plasma ctDNA Positivity in Central Nervous System Lymphoma.

  Acad Radiol, 2026. máj.

• Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy.

  J Clin Oncol, 2026. ápr.

• A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas.

  Leukemia, 2026. ápr.

• Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.

  BMC Med, 2026. márc.

• Breaking diagnostic and therapeutic barriers in intravascular large B-cell lymphoma: A 13-year real-world study from China.

  Orphanet J Rare Dis, 2026. febr.

• [Future directions in clinical development of first-line therapy for diffuse large B-cell lymphoma].

  Rinsho Ketsueki, 2026. jan.

• Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study.

  J Clin Oncol, 2025. dec.

• Dynamics of circulating tumour DNA in relapsed/refractory diffuse large B-cell lymphoma patients.

  Br J Haematol, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.